A recent study carried out by Li et al. has reported that regulators of the PI3K/AKT/mTORC1-HIF-1α have a significant role in managing MG patients and concluded that the mTOR-HIF-1α signalling could be the possible immune metabolism reprogramming checkpoint of MG [59]. The gene discussed is MTOR; the disease is myasthenia gravis.